Opendata, web and dolomites

MYELOMANEXT SIGNED

Integrated next-generation flow cytometry and sequencing to uncover the pathway of curability in multiple myeloma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MYELOMANEXT project word cloud

Explore the words cloud of the MYELOMANEXT project. It provides you a very rough idea of what is the project "MYELOMANEXT" about.

immune    outcome    longitudinally    multiple    biologically    optimal    substantial    equally    sustained    majority    group    circulating    coupled    cscs    remissions    understand    subclones    largely    prospective    ultra    flow    scope    failing    myeloma    professional    samples    sensitive    vs    ctcs    effort    cells    players    additional    irrespectively    clones    integrate    persistent    fail    hence    hierarchical    generation    driving    disease    met    cell    opposite    relies    mechanisms    therapeutic    chemoresistant    minimal    dna    sequencing    performed    genomic    cures    scientific    vast    dramatic    conduct    mm    chemoresistance    breaking    transformation    clone    residual    patient    incurable    benign    optimized    place    improvement    patients    landscape    functional    expertise    noteworthy    survival    responsible    therapy    ground    surveillance    malignant    tumour    believe    deep    model    first    mrd    relapses    innovative    signature    stem    relapse    trials    unquestionable    cellular    time    cancer    putative    clinical    overcome    cytometry    herein    rna    despite   

Project "MYELOMANEXT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE NAVARRA 

Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL
city: PAMPLONA
postcode: 31080
website: www.unav.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙468˙606 €
 EC max contribution 1˙468˙606 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) coordinator 1˙468˙606.00

Map

 Project objective

Multiple myeloma (MM) represents a unique model to investigate cancer stem cells (CSCs), circulating tumour cells (CTCs), and the mechanisms of malignant transformation and chemoresistance. Despite the substantial improvement in MM patients’ outcome, the vast majority of patients eventually relapse and the disease remains largely incurable. For those patients failing to achieve deep remissions, biologically targeted research on the ultra-chemoresistant minimal residual disease (MRD) clone may allow us to understand the cellular mechanisms driving chemoresistance, and design novel therapeutic to overcome; importantly, such effort should be equally performed on two additional key players: CSCs and CTCs. On the opposite side, it is unquestionable that a selected group of patients does experience long-term survival irrespectively of the depth of response achieved, but we fail to understand the mechanisms driving sustained disease control. Is it because of persistent residual benign clones? Is it because of immune surveillance? Here, we will integrate next-generation flow cytometry and sequencing to define i) the signature of CTCs and ultra-chemoresistant MRD cells, ii) the hierarchical place of putative CSCs, iii) the genomic landscape of benign vs. malignant clones; and iv) the role of immune surveillance to achieve functional cures. Hence, we will characterize for the first-time-ever the highly-professional subclones responsible for malignant transformation, disease dissemination, and dramatic relapses after optimal response to therapy. Noteworthy, the innovative approach of this scientific proposal strongly relies on the use and expertise of highly-sensitive next-generation flow cytometry, coupled with optimized DNA- and RNA-sequencing for low-cell-numbers, and prospective patient samples longitudinally available within the scope of well-controlled clinical trials. Herein, we believe that all requirements are met to conduct this ground-breaking research program.

 Publications

year authors and title journal last update
List of publications.
2017 Yuji Mishima, Bruno Paiva, Jiantao Shi, Jihye Park, Salomon Manier, Satoshi Takagi, Mira Massoud, Adriana Perilla-Glen, Yosra Aljawai, Daisy Huynh, Aldo M. Roccaro, Antonio Sacco, Marzia Capelletti, Alexandre Detappe, Diego Alignani, Kenneth C. Anderson, Nikhil C. Munshi, Felipe Prosper, Jens G. Lohr, Gavin Ha, Samuel S. Freeman, Eliezer M. Van Allen, Viktor A. Adalsteinsson, Franziska Michor, Jesus F. San Miguel, Irene M. Ghobrial
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
published pages: 218-224, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2017.03.025
Cell Reports 19/1 2019-06-19
2017 B Paiva, N Puig, M T Cedena, B G de Jong, Y Ruiz, I Rapado, J Martinez-Lopez, L Cordon, D Alignani, J A Delgado, M C van Zelm, J J M Van Dongen, M Pascual, X Agirre, F Prosper, J I Martín-Subero, M-B Vidriales, N C Gutierrez, M T Hernandez, A Oriol, M A Echeveste, Y Gonzalez, S K Johnson, J Epstein, B Barlogie, G J Morgan, A Orfao, J Blade, M V Mateos, J J Lahuerta, J F San-Miguel
Differentiation stage of myeloma plasma cells: biological and clinical significance
published pages: 382-392, ISSN: 0887-6924, DOI: 10.1038/leu.2016.211
Leukemia 31/2 2019-05-27
2017 P Arana, B Paiva, M-T Cedena, N Puig, L Cordon, M-B Vidriales, N C Gutierrez, F Chiodi, L Burgos, L-L Anglada, J Martinez-Lopez, M-T Hernandez, A-I Teruel, M Gironella, M-A Echeveste, L Rosiñol, R Martinez, A Oriol, J De la Rubia, A Orfao, J Blade, J-J Lahuerta, M-V Mateos, J-F San Miguel
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
published pages: 971-978, ISSN: 0887-6924, DOI: 10.1038/leu.2017.320
Leukemia 32/4 2019-05-27
2016 B. Paiva, M.-T. Cedena, N. Puig, P. Arana, M.-B. Vidriales, L. Cordon, J. Flores-Montero, N. C. Gutierrez, M.-L. Martin-Ramos, J. Martinez-Lopez, E. M. Ocio, M. T. Hernandez, A.-I. Teruel, L. Rosinol, M.-A. Echeveste, R. Martinez, M. Gironella, A. Oriol, C. Cabrera, J. Martin, J. Bargay, C. Encinas, Y. Gonzalez, J. J. M. Van Dongen, A. Orfao, J. Blade, M.-V. Mateos, J. J. Lahuerta, J. F. San Miguel
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
published pages: 3165-3174, ISSN: 0006-4971, DOI: 10.1182/blood-2016-03-705319
Blood 127/25 2019-05-27
2016 Bruno Paiva, Juana Merino, Jesús F. San Miguel
Utility of flow cytometry studies in the management of patients with multiple myeloma
published pages: 511-517, ISSN: 1040-8746, DOI: 10.1097/cco.0000000000000331
Current Opinion in Oncology 28/6 2019-05-27
2016 B. Paiva, L. A. Corchete, M.-B. Vidriales, N. Puig, P. Maiso, I. Rodriguez, D. Alignani, L. Burgos, M.-L. Sanchez, P. Barcena, M.-A. Echeveste, M. T. Hernandez, R. Garcia-Sanz, E. M. Ocio, A. Oriol, M. Gironella, L. Palomera, F. De Arriba, Y. Gonzalez, S. K. Johnson, J. Epstein, B. Barlogie, J. J. Lahuerta, J. Blade, A. Orfao, M.-V. Mateos, J. F. San Miguel
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
published pages: 1896-1906, ISSN: 0006-4971, DOI: 10.1182/blood-2015-08-665679
Blood 127/15 2019-05-27
2017 T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva, R Hajek
Current applications of multiparameter flow cytometry in plasma cell disorders
published pages: e617, ISSN: 2044-5385, DOI: 10.1038/bcj.2017.90
Blood Cancer Journal 7/10 2019-05-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MYELOMANEXT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MYELOMANEXT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUBMODULAR (2019)

The Power of Randomness and Continuity in Submodular Optimization

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More